Home
High Throughput Screening
26 April - 27 April 2010
High Throughput Screening

What is this conference about?

Screening

SAE Media Group's industry-leading High Throughput Screening conference returns for its sixth year.  The theme of this year's conference will be how to lead HTS down an intelligent route towards lead generation.

Taking place in London, UK, this conference will look at a wide range of issues within the HTS arena under several 'topic umbrellas'.  The State of the Industry will look at the best of HTS now, outsourcing and hit-to-lead bottlenecks.  Focussing HTS will investigate methods to increase the quality of the leads generated.  There will be in-depth studies into In-Silico Screening and GPCRs, and finally, a look to the future in New Screening Technologies.

Questions examined during the conference will include: how successful is HTS now?  Is outsourcing worthwhile economically?  What are the IP issues?  Can intelligent research outperform HTS?  Does iterative screening hold the key to obtaining high quality leads?  How can we redesign the HTS framework?  Do we rely on established assays too much?  Can virtual screening ever replace HTS as the standard lead generator?  How can HTS be used successfully in harnessing the power of GPCRs?  What is the potential for biophysical tools to be used in screening?

Attend this event to discover how High Throughput Screening can be made more intelligent, more focussed and more beneficial in drug discovery

 

Fancy speaking at the conference?  Do you know of anyone who may be interested in speaking?  We are always on the look-out for new speakers for our upcoming conferences.  Let us know: SAE Media Groupproduction@SAE Media Group-online.co.uk.


For sponsorship and exhibitioning opportunities, contact sponsorshipdept@SAE Media Group-online.co.uk 

Conference agenda

clock

8:30

Registration and coffee

clock

9:00

Chairman's opening remarks

Francois Bertelli

Francois Bertelli, Senior Principal Scientist, Pfizer

clock

9:10

LEAD DISCOVERY STRATEGIES - ONE SIZE FITS ALL, OR HORSES FOR COURSES?

Murray Brown

Murray Brown, Manager, Data Interpretation and Business Process, Screening and Compound Profiling, GlaxoSmithKline

  • Challenges for lead discovery
  • Different approaches to hit identification in GSK including diversity HTS, fragments and encoded libraries
  • Strengths and weaknesses of the different approaches
  • clock

    9:50

    HOW SUCCESSFUL IS HTS?

    Niklas Blomberg

    Niklas Blomberg, Associate Director, Computational Chemistry, AstraZeneca

  • Overview of new target prosecutions - comparison with the recent past
  • Number of target prosecutions compared with rise in HTS
  • Major failings of HTS - potential for overcoming
  • clock

    10:30

    HIT VALIDATION STRATEGIES

    Ulrich Hassiepen

    Ulrich Hassiepen, Research Investigator II, Novartis

  • Level of the need to reduce false positives
  • Impact of assay technologies
  • Counter-screening approaches
  • Screening in a more bio-relevant form
  • clock

    11:10

    Morning coffee

    clock

    11:40

    WHEN A MILLION IS TOO MANY - MAXIMISING HTS RETURNS FROM TRUNCATED RANDOM SCREENING SUBSETS

    Willem Nissink

    Willem Nissink, Associate Principal Scientist, AstraZeneca

  • Using an incremental HTS-set subsetting design to facilitate managing the cost of screening a >>1M compound collection
  • Rationale, implementation, expectations and results
  • Use of frequent-hitter information from historical HTS data for annotation of new screen results
  • clock

    12:20

    HCS AND MULTI-PARAMETER READOUTS: DE-RISKING DRUG DISCOVERY PROGRAMME

    Katya  Tsaioun

    Katya Tsaioun, President, Apredica

  • Technology and its validation - review
  • Mechanisms of human toxicity - how what you do not know may hurt you
  • Streamlining and reducing the cost of hit-to-lead and lead optimisation campaigns
  • Advanced lead profiling - case studies
  • clock

    13:00

    Networking lunch

    clock

    14:00

    IMAGING TECHNIQUES FOR HCS AND HTS

    Alessandro Esposito

    Alessandro Esposito, Senior Investigator Scientist, MRC Cancer Cell Unit, Cambridge University

  • Unsupervised fluorescence lifetime imaging microscopy
  • Identifying molecular or cellular sub-populations
  • Practical application and case studies
  • clock

    14:40

    ON THE IMPACT OF VIRTUAL SCREENING IN LEAD GENERATION

    Stefan Schmitt

    Stefan Schmitt, Team Leader, Computational Chemistry, AstraZeneca

  • Integration of virtual screening in the lead discovery process
  • Good practice for virtual screening
  • Performance of VS in comparison to parallel running HTS approach
  • clock

    15:20

    Afternoon tea

    clock

    15:50

    IN-SILICO VERSUS WET SCREENING IN THE CONTEXT OF INTEGRATION STRATEGIES

    George Keseru

    George Keseru, Head of Discovery Chemistry, Gedeon Richter

  • Case study involving a kinase associated with Alzheimer's and other neurodegenerative diseases
  • HTS and in-silico screening carried out separately for direct comparison of utility
  • How should the industry combine HTS and in-silico to optimise lead generation
  • clock

    16:30

    IN SILICO SCREENING IN SUPPORT OF DRUG DISCOVERY

    James Campbell

    James Campbell, Director, Lead Generation, AstraZeneca

  • Defining in silico screening - virtual screening, predictive models and database mining
  • Exploiting in silico screening - early drug discovery
  • Effective techniques in modern drug discovery
  • clock

    17:10

    Chairman’s closing remarks and close of day one

    clock

    8:30

    Re-registration and coffee

    clock

    9:00

    Chairman's opening remarks

    Peter O'Brien

    Peter O'Brien, Veterinary Clinical Pathologist, University College Dublin

    clock

    9:10

    COPING WITH PROCESS ERROR WITHIN A HIGH THROUGHPUT SCREENING CAMPAIGN

    Nicola Richmond

    Nicola Richmond, Investigator, GlaxoSmithKline

  • The impact of process error on hit rate and compound selection
  • Minimising false positives and false negatives using computational methods
  • Designing HTS compound triaging strategies in the presence of process error
  • clock

    9:50

    SCREENING AND PATHWAY BIOLOGY

    Peter Ghazal

    Peter Ghazal, Head of Division of Pathway Medicine, University of Edinburgh

  • Understanding transcriptional regulatory networks and host pathogen interactions
  • Developing new methods for mapping of complex biological systems
  • Applications in the treatment and diagnosis of immune-related diseases
  • clock

    10:30

    HOW TO OPTIMISE SCREENING ASSAYS FOR ORPHAN OR LIGANDED GPCRs

    Michel Detheux

    Michel Detheux, Director FAST Business Unit, Euroscreen SA

  • Assay development
  • Assay validation
  • Assay optimization
  • Case studies
  • clock

    11:10

    Morning coffee

    clock

    11:40

    MODELLING NANOPARTICLE AND LIGAND INTERACTION IN FLEXIBLE RECEPTOR MODELS

  • Screening with biophysical models
  • Enrichment rates for flexible receptor models
  • Towards flexible backbone simulations and induced fit
  • Wolfgang Wenzel

    Wolfgang Wenzel, Scientist, Institute of Nanotechnology, Karlsruhe Institute of Technology

    clock

    12:20

    HIGH CONTENT SCREENING: A CELL MORPHOLOGY BASED SCREEN TO IDENTIFY NOVEL REGULATORS OF CELL-CELL JUNCTIONS

    Ann Wheeler

    Ann Wheeler, Advanced Imaging Facility Manager, Queen Mary University Of London

  • High Content Imaging screen design
  • Analysis methods and data storage in High Content Imaging Screens
  • Data mining and post-hoc analysis of High Content Imaging Screens
  • clock

    13:00

    Networking lunch

    clock

    14:00

    MAXIMISING THE IMPACT OF HTS ON THE PFIZER DISCOVERY PORTFOLIO

    John Mathias

    John Mathias, Head of HTS CoE, Pfizer

  • Assessment of the impact HTS has made on the recent Pfizer portfolio
  • The design of screening subsets to increase the efficiency of primary screening campaigns
  • clock

    14:40

    APPLICATION OF HIGH CONTENT ANALYSIS (HCA) IN DISCOVERING TOXICOLOGY SCREENING STRATEGIES

    Peter O'Brien

    Peter O'Brien, Veterinary Clinical Pathologist, University College Dublin

  • Evidence for effective use of HCA in cytotoxicity assessment of human toxicity potential
  • Salient criteria for predictive cytotoxicity models
  • Interpretation and application  of HCA cytotoxicity data for optimisation and prioritisation
  • Translational cytotoxicity biomarkers for application in drug discovery and development
  • Strategies for incorporation of HCA into drug discovery safety assessment
  • clock

    15:20

    Afternoon tea

    clock

    15:50

    HTS - DEVELOPING FUTURE SUCCESS FROM PREVIOUS EXPERIENCE

    Peter Greasley

    Peter Greasley, Lead Generation Science & Strategy Manager, AstraZeneca

  • Working with target classes
  • Backing the right technologies
  • Introducing the right target with the right assay to the right chemistry
  • clock

    16:30

    THE FUTURE FOR HTS

    Francois Bertelli

    Francois Bertelli, Senior Principal Scientist, Pfizer

  • Historical benefits of HTS (including assay technologies and target classes)
  • HTS under the current climate in the pharma industry
  • Future challenges of HTS - what is Pfizer doing?
  • clock

    17:10

    Chairman’s closing remarks and close of day two

    Crowne Plaza Hotel - St James

    Buckingham Gate 45/51
    London SW1E 6AF
    United Kingdom

    Crowne Plaza Hotel - St James

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.